News

September 4, 2018

Penn’s Abramson Cancer Center Added as Second Clinical Trial Site for CPI-613 in T-cell Lymphoma

News

The Abramson Cancer Center at the University of Pennsylvania will serve as a second trial site in the Phase 1 study of CPI-613 for T-cell lymphoma patients, according to Rafael Pharmaceuticals, the drug’s developer. The ... Read more

August 28, 2018August 28, 2018

FDA Approves Imbruvica-Rituxan Combo Therapy for Rare Type of Lymphoma

News

The U.S. Food and Drug Administration (FDA) has approved Imbruvica (ibrutinib) plus Rituxan (rituximab) for the treatment of patients with a rare type of non-Hodgkin’s lymphoma called Waldenström’s macroglobulinemia (WM). This represents the first and only chemotherapy-free combination ... Read more

August 22, 2018

FDA Grants CPI-613 Orphan Drug Status For Peripheral T-Cell Lymphoma Treatment

News

Therapeutic candidate CPI-613, developed by Rafael Pharmaceuticals, received orphan drug designation by the U.S. Food and Drug Administration for the treatment of peripheral T-cell lymphoma (PTCL). This is the fifth ... Read more

August 17, 2018August 17, 2018

FDA-Approved Poteligeo for Two Types of Cutaneous T-cell Lymphoma

News

The U.S. Food and Drug Administration’s (FDA) recent approval of Poteligeo (mogamulizumab-kpkc) was based on a Phase 3 trial that showed Poteligeo significantly slowed disease progression in adults with relapsed or ... Read more

August 16, 2018

Cellectar and Orano Med Collaborating to Advance Innovative Anti-Cancer Therapy

News

Cellectar Biosciences and Orano Med, two companies using distinct strategies to develop innovative therapies for cancer, are joining forces to advance a class of anti-cancer therapies called phospholipid drug conjugates. ... Read more

August 14, 2018

First Patient Dosed in Phase 2 Trial of ADCT-402 in DLBCL

News

ADC Therapeutics has dosed the first participant in its Phase 2 trial assessing ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The trial is expected to support the ... Read more

August 9, 2018

Poteligeo Approved in US for Treating 2 Cutaneous T-cell Lymphoma Subtypes

News

Poteligeo (mogamulizumab-kpkc) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides and Sézary syndrome — two types of cutaneous T-cell lymphoma — in patients ... Read more

August 8, 2018

Gazyva-Revlimid Combo Shows Promise for Follicular Lymphoma Patients in Clinical Trial

News

Gazyva (obinutuzumab) with Revlimid (lenalidomide) — a combination called Galen — is a potentially safe and effective treatment for relapsed or refractory follicular lymphoma, with over 60% of patients responding to treatment, ... Read more

August 7, 2018

New Fluorescent Probe Able to Identify, Track Evasive Cancer Stem Cells in Mice, Study Reports

News

Scientists have developed a molecular probe that finds and illuminates cancer stem cells in human cancer cell lines and live mice. The ability to identify and track these elusive cells, ... Read more

August 6, 2018August 7, 2018

Compound Puts Cancer Cells into ‘Permanent Sleep’ in Mouse Study

News

Researchers in Australia have developed a new compound that arrests the growth and spread of cancer cells — including lymphoma — in mice, without the harmful side effects of conventional therapies. ... Read more